“Lebrikizumab vs Other Systemic Monotherapies for Moderate to Severe Atopic Dermatitis: Network Meta-analysis of Short-term Efficacy” (2025) SKIN The Journal of Cutaneous Medicine, 9(1), p. s517. doi:10.25251/skin.9.supp.517.